Inspire Medical (INSP) Fundamental Analysis: Revenue, Earnings & Valuation

1.53 / 10

Underperform

Fundamental analysis rates INSP as underperforming (1.5/10). Strengths include high interest coverage and solid fixed‑asset turnover, but cash‑to‑market, low asset‑to‑market and high debt‑to‑working‑capital weigh heavily, resulting in a low composite score of 1.53.

Analysis Checks(2/10)

Net assets per share (growth rate compared to beginning of year %)

Value17.86

Score0/3

Weight19.19%

1M Return-6.98%

Annualized return on equity (%)

Value19.77

Score1/3

Weight6.09%

1M Return-2.06%

Quick ratio

Value4.56

Score1/3

Weight5.47%

1M Return-2.25%

Fixed assets turnover ratio

Value8.42

Score2/3

Weight4.10%

1M Return-1.28%

Long-term debt to working capital ratio (%)

Value0.06

Score1/3

Weight11.33%

1M Return-3.85%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight9.11%

1M Return-3.03%

Asset-MV

Value-0.49

Score1/3

Weight12.79%

1M Return-5.03%

ROE (%)

Value19.77

Score1/3

Weight6.09%

1M Return-2.06%

Current assets / Total assets (%)

Value64.33

Score1/3

Weight9.45%

1M Return-3.34%

Cash-MV

Value-0.40

Score0/3

Weight16.39%

1M Return-8.60%

Is INSP undervalued or overvalued?

INSP scores 1.53/10 on fundamentals and holds a Premium valuation at present. Backed by its 19.77% ROE, 15.95% net margin, 9.93 P/E ratio, 1.85 P/B ratio, and 175.00% earnings growth, these metrics solidify its Underperform investment rating.